Emcure Pharmaceuticals Limited (EMCURE): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Emcure Pharmaceuticals Limited, explained in plain English.

• ▪Emcure Pharmaceuticals Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪EMCURE closed at ₹1,863.50 on 30 October 2026.
• ▪Over the past year the shares are up 39.1%, trading between ₹1,306.50 and ₹2,100.70.
• ▪Reported fundamentals show a net margin of 10.44%, debt to equity of 30.57.
• ▪Our transparent MaxGrade checklist scores it D (48/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 31.75% with a maximum drawdown of -12.66% and a beta of 0.42 against NIFTY 50.
• ▪Recent coverage: Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a look

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Figures from the current session. Market open.